Literature DB >> 9201249

Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells.

A Aviram1, A Rephaeli, M Shaklai, A Nudelman, I Ben-Dror, L Maron, E Rabizadeh.   

Abstract

Previously we have shown that pivaloyloxymethyl butyrate (AN-9), a pro-drug of butyric acid (BA), is a differentiation-inducing agent in a variety of cells. In this report, we demonstrate that AN-9 is a cytostatic but not cytotoxic agent in a myelomonocytic cell line (WEHI); thus, the cells were growth-arrested and differentiated. These late changes in the cells were preceded by changes in the expression of the early regulatory genes, c-myc and c-jun. Although initiation of all these events had already occurred after 1 h exposure to AN-9, the tumorigenicity of these cells tested in Balb/c mice was not affected. A marked reduction in the tumorigenicity of AN-9-treated cells was observed after 4 h of exposure. Exposure of the highly metastatic subclone of Lewis lung carcinoma (3LLD122) to AN-9 resulted in a very pronounced effect on the tumorigenicity of these cells tested in C57BL mice. Unlike WEHI cells, the tumorigenicity of 3LLD122 was almost completely diminished after 1 h of exposure. In both cell types a 10-fold higher concentration of BA did not affect the tumorigenicity of the cells as did AN-9.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201249     DOI: 10.1007/bf01208637

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

1.  Histone acetylation reduces nucleosome core particle linking number change.

Authors:  V G Norton; B S Imai; P Yau; E M Bradbury
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

Review 2.  Histone acetylation: a step in gene activation.

Authors:  G Vidali; N Ferrari; U Pfeffer
Journal:  Adv Exp Med Biol       Date:  1988       Impact factor: 2.622

3.  Butyrate-induced differentiation in leukemic myeloid cells - in-vitro and in-vivo studies.

Authors:  A Rephaeli; J Nordenberg; A Aviram; E Rabizadeh; Y Zimra; A Nudelman; A Novogrodsky; M Shaklai
Journal:  Int J Oncol       Date:  1994-06       Impact factor: 5.650

4.  Butyric acid: inhibition of non-leukemic and chronic myeloid leukemia granulocyte macrophage clonal growth.

Authors:  E Januszewicz; E Rabizadah; A Novogrodsky; M Shaklai
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

5.  Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9).

Authors:  E Rabizadeh; M Shaklai; L Eisenbach; A Nudelman; A Rephaeli
Journal:  Isr J Med Sci       Date:  1996-12

6.  Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells.

Authors:  Y Zimra; L Wasserman; L Maron; M Shaklai; A Nudelman; A Rephaeli
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 7.  Control of programmed cell death in normal and leukemic cells: new implications for therapy.

Authors:  L Sachs; J Lotem
Journal:  Blood       Date:  1993-07-01       Impact factor: 22.113

8.  Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.

Authors:  S J Collins; F W Ruscetti; R E Gallagher; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

9.  Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences.

Authors:  G Vidali; L C Boffa; E M Bradbury; V G Allfrey
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

Review 10.  Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation.

Authors:  G B Pierce; W C Speers
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

View more
  2 in total

1.  Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy.

Authors:  Jonathan D Edwards; Matthew E R Butchbach
Journal:  J Neuromuscul Dis       Date:  2016-11-29

2.  Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.

Authors:  L L Siu; D D Von Hoff; A Rephaeli; E Izbicka; C Cerna; L Gomez; E K Rowinsky; S G Eckhardt
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.